You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 5,541,171


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,541,171
Title: Orally administrable pharmaceutical composition
Abstract:A solid dosage form, such as a capsule or tablet, containing a pharmacologically active agent is coated with an anionic polymer, which is insoluble in gastric juice and in intestinal juice below pH7 but soluble in colonic intestinal juice, in a sufficient amount that the oral dosage form remains intact until it reaches the colon. The preferred anionic polymer is a partly methyl esterified methacrylic acid polymer in which the ratio of free carboxylic groups to ester groups is about 1:2. The invention has particular application to dosage forms of prednisolone and salts thereof, indomethacin, ibuprofen, and, especially, 5-amino-salicylic acid.
Inventor(s): Rhodes; John (Cardiff, GB7), Evans; Brian K. (Dinas Powis, GB7)
Assignee: Tillotts Pharma AG (Ziefen, CH)
Application Number:08/448,300
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Dosage form;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 5,541,171: A Comprehensive Guide

Introduction

Understanding the scope and claims of a patent is crucial for both patent holders and those navigating the intellectual property landscape. This article will delve into the specifics of United States Patent 5,541,171, exploring its claims, the patent landscape, and the implications of its scope.

Background of the Patent

United States Patent 5,541,171, titled "Orally Administrable Pharmaceutical Compositions," was issued on July 30, 1996. This patent is part of a series of patents stemming from the same parent applications filed between 1982 and 1993. The patentees, through several continuation and divisional applications, sought to patent specific formulations for the selective administration of 5-amino-salicylic acid (5-ASA) to the large intestine[2].

Claims of the Patent

The '171 patent includes claims that describe orally administrable pharmaceutical compositions designed to deliver 5-ASA or its pharmaceutically acceptable salts or esters directly to the colon. Here are some key aspects of the claims:

Claim 1

Claim 1 of the '171 patent specifies an orally administrable pharmaceutical composition for selectively administering 5-ASA, emphasizing the use of a specific coating that ensures the active agent is released in the colon rather than earlier in the digestive tract[2].

Key Differences from Related Patents

The '171 patent differs from its related patent, the '170 patent, primarily in the exclusion of certain coating mixtures. The '171 patent explicitly excludes coating mixtures of Eudragit S and Eudragit L, whereas the '170 patent does not have this exclusion[2].

Patent Landscape Analysis

To understand the position of the '171 patent within the broader patent landscape, it is essential to conduct a patent landscape analysis.

Defining Scope and Keywords

The first step involves defining the technology field and identifying relevant keywords. For the '171 patent, keywords might include "orally administrable pharmaceutical compositions," "5-amino-salicylic acid," "colon-specific delivery," and "pharmaceutical coatings"[3].

Searching and Organizing Patents

Using databases such as the USPTO's Patent Public Search, the European Patent Office's esp@cenet, and WIPO's PATENTSCOPE, one can retrieve relevant patents based on these keywords. Patents can be organized by factors like filing date, assignee, and technology subcategories[1][4].

Identifying Trends and Key Players

Analyzing the patent filings over time helps in recognizing trends and identifying key players in the field. For instance, the persistence of the patentees in filing continuation and divisional applications indicates a highly competitive and evolving field[2].

Analyzing Citations and Evolution

Studying how patents reference each other provides insights into their impact and development. The '171 patent, being part of a series of related patents, shows a complex evolution of claims and arguments against prior art[2].

Importance of Claim Scope

The scope of the claims in the '171 patent is critical for its validity and enforceability.

Avoiding Overly Broad Claims

A common misconception is that broader claims offer better protection. However, overly broad claims are more difficult to get granted and easier to invalidate. The claims in the '171 patent must be anchored to the embodiments disclosed in the specification to avoid invalidation grounds such as the abstract idea exception and failure to meet the written description requirement[5].

Balancing Scope and Specificity

The claim scope must balance between being broad enough to cover the invention's essence and specific enough to distinguish it from prior art. The '171 patent's exclusion of specific coating mixtures is a strategic move to avoid prior art and ensure the uniqueness of the invention[2].

International Patent Landscape

Given the global nature of pharmaceutical research, it is important to consider the international patent landscape.

Searching International Patent Offices

Databases like the European Patent Office's esp@cenet, the Japan Patent Office's database, and WIPO's PATENTSCOPE provide access to international patent applications and granted patents. This helps in identifying whether similar inventions have been patented abroad[1].

Global Dossier

The Global Dossier service allows users to access the file histories of related applications from participating IP Offices, providing a comprehensive view of the patent family and related citations[1].

Practical Insights for Strategic Decisions

The analysis of the '171 patent and its landscape can provide practical insights for strategic decisions.

Competitive Landscape

Understanding the competitive landscape helps in identifying potential competitors and collaborators. The persistence of the patentees in this case indicates a competitive field where continuous innovation is necessary[3].

Legal Vulnerabilities

Analyzing the claims and their evolution helps in identifying potential legal vulnerabilities. Ensuring that the claims are well-supported by the specification and distinguishable from prior art is crucial for maintaining the patent's validity[5].

Key Takeaways

  • Claim Scope: The scope of the claims must be balanced to ensure they are neither too broad nor too narrow, and must be anchored to the embodiments in the specification.
  • Patent Landscape: Conducting a thorough patent landscape analysis helps in understanding the competitive field, identifying trends, and recognizing key players.
  • International Considerations: Searching international patent databases is essential to ensure global uniqueness and to avoid potential legal conflicts.
  • Legal Vulnerabilities: Ensuring that claims are well-supported and distinguishable from prior art is critical for maintaining the patent's validity.

FAQs

Q: What is the main focus of United States Patent 5,541,171?

A: The main focus of the '171 patent is on orally administrable pharmaceutical compositions designed to deliver 5-amino-salicylic acid (5-ASA) directly to the colon.

Q: How does the '171 patent differ from the '170 patent?

A: The '171 patent explicitly excludes coating mixtures of Eudragit S and Eudragit L, whereas the '170 patent does not have this exclusion.

Q: Why is claim scope important in patent applications?

A: Claim scope is crucial because overly broad claims can be easier to invalidate, while claims that are too narrow may not provide adequate protection for the invention.

Q: What tools can be used for conducting a patent landscape analysis?

A: Tools such as the USPTO's Patent Public Search, the European Patent Office's esp@cenet, and WIPO's PATENTSCOPE can be used for conducting a patent landscape analysis.

Q: How can one ensure the validity of a patent's claims?

A: Ensuring that claims are well-supported by the specification, distinguishable from prior art, and not overly broad helps in maintaining the patent's validity.

Sources

  1. USPTO: Search for patents - USPTO. (2018, October 18). Retrieved from https://www.uspto.gov/patents/search
  2. Vlex: Medeva Pharma Suisse A.G. v. Par Pharm., Inc. - Federal Cases. Retrieved from https://case-law.vlex.com/vid/medeva-pharma-suisse-g-887126385
  3. Goldstein Patent Law: How to Do Patent Landscape Analysis. Retrieved from https://www.goldsteinpatentlaw.com/how-to-patent-landscape-analysis/
  4. Clemson University: Research and Course Guides: Patent Searching, Advanced: Overview. (2024, May 23). Retrieved from https://clemson.libguides.com/advanced_patent_searching
  5. Rimon Law: The Importance of Getting the Claim Scope Right in a US Patent Application. (2021, October 4). Retrieved from https://www.rimonlaw.com/the-importance-of-getting-the-claim-scope-right-in-a-us-patent-application-i/

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 5,541,171

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 5,541,171

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom8123573Jul 31, 1981

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.